![Foto de ROSA MARÍA](/img/nophoto.png)
ROSA MARÍA
AYALA DÍAZ
Profesora titular de universidad
Publicaciones (103) Publicaciones de ROSA MARÍA AYALA DÍAZ
2024
-
Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges
Frontiers in Immunology, Vol. 15
-
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851
-
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
Cancer
-
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
Haematologica
2023
-
Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
JCI Insight, Vol. 8, Núm. 2
-
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681
-
Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
Life, Vol. 13, Núm. 9
-
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma (Journal of Hematology & Oncology, (2023), 16, 1, (76), 10.1186/s13045-023-01474-w)
Journal of Hematology and Oncology
-
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
Frontiers in immunology
-
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients (Frontiers in Immunology, (2023), 14, (1188818), 10.3389/fimmu.2023.1188818)
Frontiers in Immunology
-
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Journal of Hematology and Oncology
-
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
The Lancet, Vol. 401, Núm. 10373, pp. 269-280
-
Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE
Frontiers in Pharmacology, Vol. 14
-
Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia
Leukemia, Vol. 37, Núm. 8, pp. 1649-1659
-
Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT
Leukemia, Vol. 37, Núm. 3, pp. 659-669
-
Should we move to a genomic classification of neutrophilic myeloid neoplasms?
Blood Advances
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
-
Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched cohorts study
Clinical Infection in Practice, Vol. 13
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23